Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 112742974 | 11274297 | 4 | F | 20150731 | 20150715 | 20160725 | EXP | US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-044609 | BRISTOL MYERS SQUIBB | 0.00 | M | Y | 0.00000 | 20160725 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 112742974 | 11274297 | 1 | PS | ATAZANAVIR SULFATE | ATAZANAVIR SULFATE | 1 | Transplacental | 300 MG, QD | 21567 | 300 | MG | QD | |||||||
| 112742974 | 11274297 | 2 | SS | ATRIPLA | EFAVIRENZEMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Transplacental | 1100 MG, QD | 0 | 1100 | MG | FILM-COATED TABLET | QD | ||||||
| 112742974 | 11274297 | 3 | SS | ATRIPLA | EFAVIRENZEMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Transplacental | 1100 MG, QD | 0 | 1100 | MG | FILM-COATED TABLET | QD | ||||||
| 112742974 | 11274297 | 4 | SS | NORVIR | RITONAVIR | 1 | Transplacental | 100 MG, QD | 0 | 100 | MG | QD | |||||||
| 112742974 | 11274297 | 5 | SS | TRUVADA | EMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Transplacental | 500 MG, QD | 0 | 500 | MG | QD | |||||||
| 112742974 | 11274297 | 6 | SS | STRIBILD | COBICISTATELVITEGRAVIREMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Transplacental | 800 MG, QD | 0 | 800 | MG | QD | |||||||
| 112742974 | 11274297 | 7 | SS | METRONIDAZOLE. | METRONIDAZOLE | 1 | Transplacental | UNK | U | 0 | |||||||||
| 112742974 | 11274297 | 8 | SS | NIFEDIPINE. | NIFEDIPINE | 1 | Transplacental | UNK | U | 0 | |||||||||
| 112742974 | 11274297 | 9 | SS | ONDANSETRON | ONDANSETRON | 1 | Transplacental | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 112742974 | 11274297 | 1 | Product used for unknown indication |
| 112742974 | 11274297 | 2 | Product used for unknown indication |
| 112742974 | 11274297 | 4 | Product used for unknown indication |
| 112742974 | 11274297 | 5 | Product used for unknown indication |
| 112742974 | 11274297 | 6 | Product used for unknown indication |
| 112742974 | 11274297 | 7 | Product used for unknown indication |
| 112742974 | 11274297 | 8 | Product used for unknown indication |
| 112742974 | 11274297 | 9 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 112742974 | 11274297 | CA |
| 112742974 | 11274297 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 112742974 | 11274297 | Congenital bladder anomaly | |
| 112742974 | 11274297 | Foetal exposure during pregnancy |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 112742974 | 11274297 | 1 | 20150519 | 20150624 | 0 | |
| 112742974 | 11274297 | 2 | 20150519 | 0 | ||
| 112742974 | 11274297 | 3 | 20150625 | 20150709 | 0 | |
| 112742974 | 11274297 | 4 | 20150519 | 20150624 | 0 | |
| 112742974 | 11274297 | 5 | 20150519 | 20150624 | 0 | |
| 112742974 | 11274297 | 6 | 20150709 | 0 |